Clinical trial
Vorinostat in Treating Patients With Metastatic or Unresectable Melanoma
NCT00121225 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00121225 |
|---|---|
| Title | Vorinostat in Treating Patients With Metastatic or Unresectable Melanoma |
| Official title | A Phase II Study of Vorinostat in Patients With Advanced Melanoma |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Ciliary Body and Choroid Melanoma, Medium/Large Size, Extraocular Extension Melanoma, Iris Melanoma, Uveal Melanoma, Recurrent Intraocular Melanoma, Recurrent Melanoma, Stage IV Melanoma |
| Intervention type | Drug |
| Interventions | vorinostat |
| Enrollment | 32 |
| Start date | Sep 1, 2005 |
| Primary completion | Mar 1, 2009 |
| Completion | Jun 1, 2013 |
| First posted | Jul 21, 2005 |
| Last update posted | Jan 29, 2019 |
| Countries | Canada, United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: